ライフサイエンスコーパス: alive

1 atively compatible with, since the mother is alive.

2 At 6 months, 75 patients (68.2%) were alive.

3 d in hospital, and one-fourth was discharged alive.

4 n how the Psp response keeps bacterial cells alive.

5 All other patients were discharged alive.

6 pool of cancer cells that are quiescent but alive.

7 n after a 6-month follow-up and are well and alive.

8 tor questionnaire was sent to patients still alive.

9 ollow-up, 302 of the 475 patients (64%) were alive.

10 , 1.06-1.56; P = .0109) for being discharged alive.

11 accumulation and requires the bacteria to be alive.

12 while at a potential of 1 V, 92+/-2.4% were alive.

13 pleted for 299 (99%), of whom 169 (57%) were alive.

14 ironment, leaving both the host and pathogen alive.

15 umor progression, the other 10 patients were alive.

16 n to a metabolically active state and remain alive.

17 78) were dichotomized as died or discharged alive.

18 n "opt-out" policy, or donate a kidney while alive.

19 was found in OPTN + all (OPTN + all [Assumed Alive]).

20 y (cause-specific hazard ratio for discharge alive=0.73; 95% CI, 0.51-0.94).

21 pes simplex encephalitis (n = 115), who were alive 1 year after diagnosis, were identified.

22 with scores 7 or more and less than 11 were alive 1 year later.

23 les were taken at 1, 3, and 6 months and (if alive) 1 year.

24 ith CRC in England in 2010 and 2011 who were alive 12 to 36 months after diagnosis were sent a questi

25 cohort of 388,422 Danish singleton boys born alive (1997-2008), we studied the association between pl

26 up of 27 months, 44 (90%) of 49 patients are alive, 21 of whom (48%) are on steroid.

27 complications and eight patients (88%) were alive 24 hours after intubation.

28 nts and 21 (87%) TBP>30% patients were still alive; 27 (32%) and 11 (46%), respectively, continued to

29 ars or older admitted with first-time MI and alive 30 days after discharge.

30 19 (95%) of 20 patients alive 30 days after implantation were NYHA class I or II

31 CRT treatment sequence showed that patients alive 4 months after diagnosis derived a survival benefi

32 Forty-four of 78 patients were alive 4.7+/-0.6 y after PET.

33 The majority (9 of 12) remained alive 6 to 9 years after diagnosis.

34 rs, 301 of the 416 index-patients presenting alive (72%) experienced sustained ventricular arrhythmia

35 At follow-up, 23 patients were alive, 8 expired, and 8 transplanted.

36 m the parent trial who were last known to be alive, a subset of 1803 children balanced by treatment g

37 namic topographical and metabolic changes in alive adherent mammalian cells.

38 2,098 unselected patients, 73.1% were still alive after 10 years.

39 ACT+Abraxane group 100% of the animals were alive after 120days vs. 0% for the Abraxane(R) only grou

40 ative 30-day mortality was 20%, and 60% were alive after 30 years of follow-up.

41 while only 50% of the target cells remained alive after 48 h incubation.

42 or equal to 24 months and two patients still alive after 50 and 66 months.

43 ger OS, especially in the VMP arm (66%remain alive after 8 years).

44 g 20976 Medicare-insured patients discharged alive after acute MI, 10381 (49.5%) were men; mean (SD)

45 3 patients with diabetes mellitus discharged alive after AMI from 24 US hospitals and then validated

46 care patients older than 65 years discharged alive after an AMI between January 2, 2007, and October

47 ygen-free days were defined as any day while alive after diagnosis of RSV infection during which </=2

48 sults: Of 17419 Medicare patients discharged alive after MI, 4674 (27%) were dual eligible.

49 ipheral arterial disease who were discharged alive after peripheral arterial revascularization, the 3

50 events were common among patients discharged alive after severe sepsis hospitalization (29.5%; 498.2

51 ive donors were more likely to be discharged alive after transplantation (95.4% vs. 93.9%, p = 0.006)

52 It included patients who were alive and 40-70 years old, and it excluded instances in

53 uced fluids suggest that these organisms are alive and active under simulated reservoir conditions.

54 diagnosis had an excellent chance of staying alive and disease free in additional subsequent years, r

55 of disseminated disease and 52 patients were alive and disease free without extranodal metastasis (me

56 essment was undertaken for patients who were alive and disease free, which included measurement of le

57 antation, 102 BM and 93 PB participants were alive and eligible for assessment (age >/=40 years or ol

58 pportunity to self-report (ie, patients were alive and enrolled in a treatment trial at the time of t

59 toff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared wi

60 The primary outcome was ICU-free days (days alive and free from the need for intensive care) from ra

61 Patients experienced more days alive and free of delirium and coma with both total bund

62 agnosis related group codes), and discharged alive and free of documented cerebrovascular disease or

63 kidney failure and (2) median number of days alive and free of kidney failure for patients who did no

64 n reported; 15 of the 17 patients (88%) were alive and free of major functional disability, with mini

65 We used the number of days alive and free of mechanical ventilation on day 28 as a

66 etween gentamicin use and the number of days alive and free of renal failure, shock, and death, all o

67 corrected multiple logistic regression, days alive and free of ventilation (p < 0.0001, p = 0.0002, a

68 lity, we determined the associations of days alive and free of ventilation, vasopressors and renal re

69 Days alive and free of ventilation, vasopressors, and renal r

70 Days alive and free of ventilation, vasopressors, and renal r

71 n contrast, Tsc1 single-mutant mice were all alive and had far fewer renal cysts at this age.

72 A total of 479 patients with ALS were alive and had not undergone tracheostomy at the prevalen

73 o received nusinersen were more likely to be alive and have improvements in motor function than those

74 The primary end point was being alive and having no major functional disability at 24 mo

75 vs 79 (60.2%) in the placebo group who were alive and IFI free (hazard ratio [HR], 1.35 [95% CI, 0.8

76 All others were alive and in remission at last follow-up (median, 14.7 m

77 19%) survived to hospital discharge and were alive and in remission of their hematologic disease afte

78 ong 858 enrolled patients, 646 patients were alive and in the hospital on day 4 and included in the m

79 cular treatment group were more likely to be alive and independent at 10 years than were patients in

80 For both alive and lyophilized probiotic mixtures, reduction of l

81 Reversal of AKI was defined as alive and no longer meeting criteria for even stage 1.

82 ating future demented subjects from subjects alive and nondemented 10 years later and an AUROC of 0.7

83 At 4 months, all patients were alive and none were lost to follow-up.

84 mortality (11% vs 1%, P = .004), fewer days alive and nonhospitalized (73 vs 81, P = .039), and decr

85 rtality, total hospitalizations for HF, days alive and not hospitalized for cardiovascular reasons, t

86 hese 4 groups, 1-year probabilities of being alive and off all systemic immunosuppression were 61%, 5

87 se cardiovascular events and home time (days alive and out of a hospital or skilled nursing facility)

88 size, and the duration of time subjects was alive and out of hospital (P=0.05).

89 zation 90 days pre-LT and the number of days alive and out of the hospital (DAOH) 1 year post-LT.

90 with viruses detected pre-HCT had fewer days alive and out of the hospital and lower survival at day

91 In the first year after TAVR, patients were alive and out of the hospital for a median of 353 days (

92 rence was observed in the proportion of days alive and out of the hospital to 1 year (rate ratio: 1.0

93 Death, stroke, and days alive and out of the hospital to 1 year were compared, a

94 group differences were found for median days alive and out of the hospital within 30 days of surgery

95 The primary outcome of days-alive and out-of-hospital was examined on an intention-t

96 2% [95% confidence interval, 85.1-89.3] days-alive and out-of-hospital; P=0.020).

97 The proportion of patients alive and progression free at 24 weeks did not differ be

98 mary endpoint was the proportion of patients alive and progression free at 24 weeks in the intention-

99 Of 202 CCM-ID physicians, 196 were alive and reachable.

100 In the 113 patients who were alive and reintervention free, the follow-up gradient (m

101 Patients who continued, alive and relapse free, were censored at their last know

102 Patient 1 is alive and remains disease-free 36 months after completio

103 years after treatment with ipilimumab, he is alive and shows no evidence of melanoma on the basis of

104 The primary outcome was number of days alive and was assessed as delirium-free and coma-free in

105 All patients are alive and well with no new vascular events and resolutio

106 The patient was alive and well, with no evidence of recurrence, at the 1

107 of 145,456 singleton full-term infants born alive and whose mothers were covered by the Regie de l'a

108 ith ascertained vital status, 340 (69%) were alive and, in 278 (82%) cases, updated care status was o

109 ely 34 months), 25/30 (83.33%) patients were alive, and 21/30 (70.00%) remained free of disease.

110 months, 20% remain progression free, 66% are alive, and 4% remain on treatment.

111 nse was not yet reached; all responders were alive, and eight had responses lasting 12 months or long

112 e Critically Ill category, time to discharge alive, and protein and energy intake, whereas in the 4-d

113 o-first event, unmatched win-ratio, and days-alive-and-out-of-hospital composites are derived for com

114 er, the effect of IOP was not significant in alive animal with the same IOP setting.

115 the New York City HIV surveillance registry alive as of 1 January 2013 and diagnosed with HIV as of

116 following care categories: (1) diagnosed and alive as of June 1, 2016; (2) retained in care; (3) appr

117 om July 4, 1965, through March 28, 1973, and alive as of survey receipt as part of Department of Vete

118 igible for CT (patients progression free and alive at 1 year after random assignment).

119 assist device (LVAD) were more likely to be alive at 1 year on original therapy with >/=75-m improve

120 Although 75% of the intervention group was alive at 1 year, 69% with usual care survived the year (

121 during the period from 1980 to 2010 who were alive at 1.5 years of age and followed up through 2013.

122 only 50% of renal transplant recipients are alive at 10 years due to the toxicities of immunosuppres

123 and 10 (0.24% to 0.48%); 9% of patients were alive at 10 years.

124 Eleven of the 14 HT patients were alive at 10+/-8 years.

125 2011, without lethal malformations and still alive at 12 hours of life were eligible for inclusion in

126 ough 1973, in otherwise healthy children and alive at 15 years of age.

127 Compared with patients alive at 180 days, patients who died were older, had low

128 Twenty percent of patients were alive at 2 years.

129 complication, and 67(35%) of those who were alive at 28 days were parenteral nutrition free.

130 ectively; 87%, 89%, and 80% were known to be alive at 3 years.

131 era, with more than 80% of treated patients alive at 3 years.

132 Of the 4530 alive at 30 days after HT, 3694 (82%) and 836 (18%) were

133 Of the remaining 3 patients, 2 were alive at 4 and 17 months and 1 was too sick to return.

134 ne is maintained with twice as many patients alive at 5 years compared with those who initially recei

135 ents of about 2 years, and less than 10% are alive at 5 years.

136 In patients who were alive at 6 months (median follow-up, 42 months; interqua

137 ears) without pre-existing dementia who were alive at 6 months follow-up.

138 At last evaluation, 277 patients (91%) are alive at 62+/-13 years of age, including 89% in New York

139 Five of the six long-term responders alive at a median of 4.5 years lacked germline BRCA1/2 m

140 Of 1037 original participants, 1007 were alive at age 38 years, of whom 565 (56%) had been lead t

141 Of 891 analyzed patients, 630 were alive at analysis (median follow-up, 3.8 years).

142 urvival was 14.0 years; 64% of patients were alive at censor.

143 not from CHD, and 1050 participants who were alive at conclusion of the trial.

144 patients overall; all responders were still alive at data cutoff.

145 umber of ICU-free and hospital-free days and alive at day 28 (10.0 +/- 10.9 vs 13.8 +/- 11.6 d; p < 0

146 ICU mortality, and ventilator-free days and alive at day 28 were retrospectively analyzed using regr

147 Five (42%) were alive at day 90.

148 was higher in patients who died versus those alive at end of study (185+/-668 versus 17+/-482 mm Hg.d

149 Seventeen of these patients were alive at follow-up.

150 d to therapeutic hypothermia during CPR were alive at hospital discharge compared with 11.4% who rece

151 Overall, 9 of 24 patients (37.5%) were alive at last follow-up with a median follow-up of these

152 Of those patients alive at LT discharge, 24.7% spent >/=30 days hospitaliz

153 All patients are alive at median follow-up 7.4 years (range, 2.7 to 10 ye

154 viduals born during the period 1967-2008 and alive at record linkage (2012).

155 d the projected survival of persons who were alive at the end of the trial.

156 Of 2348 NVVRS participants, 1920 were alive at the outset of the NVVLS, and 81 died during rec

157 th pembrolizumab who developed vitiligo were alive at the time of analysis, with a median follow-up o

158 bryonal rhabdomyosarcoma), all patients were alive at the time of analysis.

159 Six of the 7 patients were alive at the time of last follow-up (mean and median fol

160 -up questionnaire was mailed to all patients alive at the time of the study.

161 ch to assess the mortality of women who were alive at their final WISE contact date.

162 Median follow-up time for patients alive at time of analysis was 33 months (range, 11 to 93

163 than 9% (at 6 months, 33% v 69% of patients alive; at 1 year, 17% v 49% of patients alive; log-rank

164 that underwent randomization, 1566 were born alive before 30 weeks of gestation; of these, 782 were a

165 terial revascularization and were discharged alive between 1 January and 30 November 2014.

166 AMI patients treated with PCI and discharged alive between April 2010 and September 2012.

167 nal Registry with all renal transplanted men alive between January 1, 1995 and December 31, 2015 were

168 immature OLs, while more mature OLs remained alive but had reduced myelin-like membranes.

169 CPEB2-knock-out (KO) mice are born alive but most die within 3 d after birth showing no ove

170 re after 180 days (33%; n = 2,976) and being alive but not in care in the Western Cape (25%; n = 2,25

171 hospital admission, other hospital contact, alive but not in care, no information) after disengageme

172 ed (4% official and 10% unofficial), 6% were alive but out of care, 6% died in care (<60 days after l

173 Vaccines that keep hosts alive but still allow transmission could thus allow very

174 In addition, 19 patients were alive, but their melanoma metastasized, by the end of th

175 both more abnormal in deceased than in those alive by day-28 follow-up (both P<0.05, findings consist

176 Eligible patients were rescued alive by MEDEVAC from point of injury with either (1) a

177 ) of 993 patients died, and 844 patients are alive (censored rate, 85.0%).

178 een type of marriage and the total number of alive children and number of dead children among the thr

179 ot on surveillance who developed cancer were alive compared with 16 (84%) of the 19 individuals under

180 well as the subset of LTFU patients who were alive, contacted in person by the tracer, and out of car

181 nce of OHCA patients transported to hospital alive did not change over the past decade.

182 ildren (median age 9.3 years) who were still alive following SAM inpatient treatment between July 12,

183 15 170 008 Medicare patients discharged alive from 2000 to 2013.

184 nts: 15 170 008 Medicare patients discharged alive from 2000 to 2013.

185 taneous coronary intervention and discharged alive from 233 hospitals in the Treatment With Adenosine

186 ts with acute MI aged >/=65 years discharged alive from 451 US hospitals in Acute Coronary Treatment

187 maries from 1640 (91.5%) patients discharged alive from 46 hospitals.

188 65 years of age and who had been discharged alive from 545 U.S. hospitals between April 2011 and Dec

189 cohort study was based on adults discharged alive from a Canadian trauma system (1999-2010; n = 126,

190 Consecutive adult patients discharged alive from ICU to hospital wards between September 2009

191 of days in the ICU and as time to discharge alive from ICU.

192 We assessed all children born alive from January 1, 1980, through December 31, 1991, i

193 s were consecutive adult patients discharged alive from the ICU between September 2009 and February 2

194 We studied 10,211 patients discharged alive from the ICU.

195 y or secondary insurance and were discharged alive from the index LT hospitalization (n = 7019).

196 he probability of a child's being discharged alive from the pediatric intensive care unit by a given

197 ts who underwent surgery and were discharged alive from Veterans Affairs hospitals for orthopedic, ge

198 or older at time of study, 3010 (54.5%) were alive, had enrolled, and had had prospective clinical as

199 erences between groups in time to extubation alive (hazard ratio [HR], 1.16 for short- vs long-course

200 ime to termination of mechanical ventilation alive (hazard ratio, 1.43; 95% CI, 1.06-1.93; p = 0.02 a

201 ctively) and a shorter time to ICU discharge alive (hazard ratio, 1.76; 95% CI, 1.30-2.39; p < 0.001

202 fish oil had a faster time to ICU discharge alive (hazard ratio, 1.84; 95% CI, 1.01-3.34; p = 0.05).

203 % CI, .55-1.22]), time to hospital discharge alive (HR, 1.07 [95% CI, .91-1.26]), or hospital death (

204 The primary outcome was the number of alive ICU-free days at Day 28.

205 back mode in three different conditions: (i) alive; (ii) fixed, and (iii) fixed and permeabilized.

206 f 7,977 individuals in 186 species that were alive in 1971 and monitored in 13 mortality censuses ove

207 re included in the cohort if they were still alive in 1996.

208 We included 35 951 354 people alive in 2001 who were aged between 10 and 74 years in e

209 Globally, of the 7.33 billion people alive in 2015, an estimated 36.0 million (80% uncertaint

210 median follow-up for the 250 patients still alive in April 2014 was 26.3 years (range, 22.7 to 29.7

211 lower mortality and faster time to discharge alive in high-risk, longer stay patients but not signifi

212 Prospective cohort of all individuals alive in Scotland with type 1 diabetes who were aged 20

213 13.1, 19.0) of all Vietnam veterans who were alive in the 1980s were deceased.

214 , 35 (92%) of 38 patients were engrafted and alive in the cyclophosphamide 50 mg/kg cohort and 35 (85

215 or the non-detection of individuals that are alive in the population but not detected, and thus, the

216 ecific quarter given that the individual was alive in the previous quarter) were lower among the curr

217 They are still alive in their 30s and 40s and show predominant ataxia a

218 vival was excellent (10 [91%] of 11 patients alive), including a patient who had undergone liver tran

219 ents alive; at 1 year, 17% v 49% of patients alive; log-rank P = .001).

220 to occur, but vaccinated hosts can both stay alive longer and shed the virus.

221 tients allocated neurosurgical clipping were alive (odds ratio [OR] 1.35, 95% CI 1.06-1.73).

222 ercutaneous coronary intervention discharged alive on ADPri therapy from 233 United States TRANSLATE-

223 The median follow-up duration for patients alive on April 1, 2014, was 51 months (interquartile ran

224 We recruited all patients, alive on arrival, with confirmed Ebola virus disease who

225 this ambulatory advanced HF cohort remained alive on medical therapy.

226 Participants alive on or after April 1, 2003, in the Veterans Aging C

227 100 age- and sex-matched population controls alive on the date of the case's diagnosis.

228 iscordance in the hospital discharge status (alive or dead) for only 0.47% of all linked records (kap

229 iotic strains, their combinations and forms (alive or lyophilized) in nonalcoholic fatty liver diseas

230 ical cure 14 days post antibiotic cessation, alive organ failure-free days at Day 14, and duration of

231 dmissions in 180 days and the number of days alive out of the hospital in 180 days.

232 2-1.37; P=0.99) or the median number of days alive outside of the hospital (178 versus 179 days for N

233 patients with a negative (18)F-FDG PET were alive (P < 0.0001).

234 y with 45% versus 24% of patients discharged alive (P<0.001), and after adjustment for prognostic fac

235 The median follow-up in alive patients is currently 19.1 years.

236 median follow-up time from diagnosis for all alive patients was 4.9 years (range 0.3-39.6), with a me

237 ing a median follow-up of 4.2 years (5.9 for alive patients), 392 patients died.

238 Among patients found to be alive, personally contacted, and out of care, tracing in

239 robiotic "Symbiter" containing biomass of 14 alive probiotic strains (Lactobacillus + Lactococcus (6

240 of probiotic mixture with the preference of alive probiotic strains.

241 els were also inversely associated with days alive (r = -0.24; p = 0.010) and positively associated w

242 rug delivery was not a significant effect in alive rabbit eyes; however, choroidal circulation seems

243 ozen-hydrated (vitrified), and 3), initially alive states.

244 confirmed coronary artery disease discharged alive, STEMI patients (compared with non-ST-segment-elev

245 Compared with patients who were alive, those who died had more frequent history of heart

246 Alive & Thrive was implemented over a period of 6 y (200

247 beneficiaries 21 to 64 years of age who were alive throughout the calendar year (8.7 million person-y

248 ed in vivo with ultrasonic pulses and remain alive to demonstrate robust gene expression.

249 rol most other aspects of phenotype: to stay alive, to divide, and to move about.

250 ned conceptions to the contrary, taxonomy is alive today although constantly struggling for survival

251 H; Equus ferus przewalskii), the only horses alive today not successfully domesticated by humans, and

252 Here, we utilized alive tumor tissues in ex-vivo platform termed CANscript

253 essure and by such may maintain the penumbra alive until reperfusion.

254 5) patients, mortality and time to discharge alive up to day 60 were assessed relative to nutritional

255 Administration from birth of both alive (VII) and lyophilized (VI) probiotic mixture lead

256 tilator death and time to hospital discharge alive vs hospital death using competing risks models amo

257 We compared time to extubation alive vs ventilator death and time to hospital discharge

258 ndergone Tx, 35% were deceased, and 16% were alive waiting.

259 dian follow-up for patients last known to be alive was 35.2 months (IQR 22.9-39.9).

260 idence of OHCA patients who were transported alive was 36 cases per 100 000 persons and did not signi

261 -to-treat analysis, the estimated proportion alive was 77.9% in the intervention and 72.8% in the con

262 median hospital stay in patients discharged alive was longer (16 d [range, 2-240 d] vs 9 d [range, 1

263 discharge from the intensive care unit (ICU) alive were ascertained from clinical trial data.

264 ation and/or amputation) and were discharged alive were identified in the 2013 to 2014 Nationwide Rea

265 -up of 113.3+/-71.5 months, 92 patients were alive, whereas 4 died from noncardiac causes.

266 em executed-either shot, beheaded, or burned alive-while the rest died on Mount Sinjar from starvatio

267 on the outcome of fetuses and children born alive with a CHD.

268 All patients were alive with a functioning graft at the end of follow-up.

269 Medical benefit, defined as alive with a Kansas City Cardiomyopathy Questionnaire su

270 ts bridged to LuTx on awake ECLS (N = 6) are alive with a median follow-up of 10.8 months (range, 6-2

271 ents with Fanconi anemia-D1 subtype are born alive with biallelic mutations in this gene.

272 nty-six (42%) of 62 patients were discharged alive with Cerebral Performance Category 1 or 2 versus 2

273 atients had lower platelet counts than those alive with CFLD (143 versus 258 U/L, P = 0.004) or those

274 tic cohort included 1567 patients discharged alive with complete HRQOL data.

275 (1.3%) developed metastatic disease and are alive with confirmed metastases (n = 9) or have died of

276 Three of them died, and 1 is alive with hepatic metastasis.

277 10.0 years (2.5-17 years), all patients were alive with no history of late complications.

278 At 1-year post-VAD, 52% of AMI patients were alive with ongoing device support, 25.7% had been transp

279 1 month post-VAD, 91.8% of AMI patients were alive with ongoing device support, 7.2% had died on devi

280 patients had a favorable outcome at 1 year (alive with reasonable quality of life [KCCQ-OS score, >/

281 At hospital discharge, all patients remained alive, with 1 nondisabling stroke (2.0%) and 1 life-thre

282 At the end of follow-up, 70 patients were alive, with 67 patients being free of disease.

283 atients progressed and 21 of 31 (68%) remain alive, with 8 (26%) deaths related to new-onset graft-ve

284 At 5 years, 16 patients were alive, with a 5-year overall survival rate of 41% +/- 8%

285 The median number of days alive without antibiotics and mechanical ventilation at

286 Three patients with stable disease are alive without any evidence of progression during 24 to 2

287 portion of 12-hour ICU shifts patients spent alive without coma (Sedation Agitation Scale </= 2) or d

288 The mean number of days alive without delirium and without coma at day 14 did no

289 st follow-up, 174 (94%) of 185 patients were alive without disease, and four patients with disease.

290 Seven of the 15 patients are currently alive without disease.

291 nt was event-free survival, defined as being alive without graft failure; risk factors were studied u

292 At 1 year, the probability of being alive without HF hospitalization was 94% for a typical p

293 turned to care (some "silently") or remained alive without hospitalization, suggesting that many who

294 ate using the prespecified end point (LRF or alive without LRF and followed < 3 years), and 20% (95%

295 -day invasive ventilator-free days (ie, days alive without mechanical ventilation), duration of ICU a

296 s (75%; 90% confidence interval, 65-84) were alive without progressive disease at 6 months (primary e

297 herapy with gemcitabine for 6 months and was alive without recurrence 6 years later.

298 cal support, with only 52% of these patients alive without support after the first 6 months.

299 or >/=1 year, 21 (50%) were relapse-free and alive without systemic immunosuppression at 1 year after

300 At 6-month follow-up, all patients remain alive, without hospital readmission for heart failure an